Prothena Corporation plc share price logo

Prothena Corporation plc

NASDAQ: PRTA

Small Cap

$10.96

+0.17

(+1.53%)

Live

as on

Prothena Corporation plc Stock Performance

as on May 6, 2026 at 4:09 am IST

  • Day's Low

    Day's High

    $10.89
    $11.25
    downward going graph

    0.64%

    Downside

    2.65%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $4.32
    $11.69
    downward going graph

    60.58%

    Downside

    6.66%

    Upside

    downward going graph

Prothena Corporation plc share price movements today

Previous Close
$10.79
Open
$10.89
Volume
183.9K
Day's Low - High
$10.89 - $11.25
52 Week Low - High
$4.32 - $11.69

Prothena Corporation plc Historical Returns

1 Month Return
+ 9.43 %
3 Month Return
+ 29.22 %
1 Year Return
+ 33.54 %
3 Year Return
-86.27 %
5 Year Return
-55.25 %

Prothena Corporation plc Stock Fundamentals & Key Indicators

Check Prothena Corporation plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$580.9M

EPS (TTM)

0.64

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0.8

EBITDA

-183.7M

Revenue (TTM)

9.7M

Profit Margin

0.00%

Return On Equity TTM

-63.62%

Prothena Corporation plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Prothena Corporation plc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Prothena Corporation plc image
Prothena Corporation plc
BUY$580.9M-55.25%NA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.8B124.56%74.6712.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.3B100.99%27.732.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$33.0BNA118.865.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$73.5B47.01%17.1229.65%

Stock Returns calculator for Prothena Corporation plc Stock including INR - Dollar returns

The Prothena Corporation plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Prothena Corporation plc investment value today

Current value as on today

₹1,53,321

Returns

₹53,321

(+53.32%)

Returns from Prothena Corporation plc Stock

₹35,644 (+35.64%)

Dollar Impact

₹17,677 (+17.68%)

Analyst Recommendation on Prothena Corporation plc Stock

Based on 17 analysts

BUY

76.47%

Buy

23.53%

Hold

0.00%

Sell

Based on 17 analysts, 76.47% of analysts recommend a 'BUY' rating for Prothena Corporation plc. Average target price of $21

Prothena Corporation plc Share Price Target

Get share price movements and forecasts by analysts on Prothena Corporation plc.

What analysts predicted

47.81%UPSIDE

Target Price

$21

Current Price

$10.96

Analyzed by

17 Analysts

Target

$21.00

Prothena Corporation plc target price $21, a slight upside of 47.81% compared to current price of $10.96. According to 17 analysts rating.

Prothena Corporation plc Stock’s Investor Sentiment and Interest

Search interest for Prothena Corporation plc Stock has decreased by -27% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-27% versus previous 30 day period

Prothena Corporation plc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
84
0
0
132
0
2
2
4
2
0
Gross Profit
26
-61
0
132
0
2
2
4
-26
0
Operating Income
10
-78
-81
58
-66
-64
-65
-84
-40
-27
EBITDA
10
-78
-81
58
-66
-64
-65
-51
-35
-20
Interest Expense
-
6
-
-
-
-
-
-
-
-
Depreciation
5
-4
0
0
0
0
0
0
0
0
Income Before Tax
24
-64
-74
64
-59
-59
-61
-80
-36
-21
Income Tax Expense
3
3
-2
-2
0
-1
-1
44
0
0
Net Income
21
-67
-72
66
-59
-57
-60
-125
-36
-21
Net Profit Margin
25.81%
-21353.16%
-144478.00%
50.67%
-6082.58%
-2729.91%
-2128.54%
-2845.41%
-1513.08%
-102804.76%

Prothena Corporation plc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
27
0
0
0
200
53
91
135
9
Gross Profit
1
27
-100
-50
0
200
53
91
135
5
Operating Income
-159
-155
-158
-85
-112
71
-131
-191
-154
-184
EBITDA
-157
-152
-152
-84
-105
78
-130
-190
-153
-197
Interest Expense
0
3
3
8
8
6
6
-
-
-
Depreciation
-
3
3
6
6
6
0
0
0
0
Income Before Tax
-158
-157
-156
-77
-111
71
-125
-160
-128
-200
Income Tax Expense
1
-4
0
0
0
4
-8
-13
-6
43
Net Income
-160
-153
-155
-77
-111
66
-116
-147
-122
-244
Net Profit Margin
-15176.11%
-556.84%
-16297.91%
-9542.63%
-13029.78%
33.39%
-216.95%
-160.91%
-90.49%
-2520.57%

Prothena Corporation plc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-67
-72
66
-59
-57
-60
-125
-36
-21
Operating Cash Flow
-51
-73
15
-45
-47
-53
-46
-40
-27
Investing Cash Flow
-1
0
0
0
0
0
0
0
0
Financing Cash Flow
0
0
0
0
0
0
0
0
0
Change in Cash
-52
-72
16
-44
-47
-53
-46
-40
-23

Prothena Corporation plc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-153
-155
-77
-111
66
-116
-147
-122
-244
Operating Cash Flow
-131
-28
-52
-80
92
-108
-133
-150
-163
Investing Cash Flow
-3
-1
0
0
0
0
-2
0
0
Financing Cash Flow
165
40
0
0
190
241
45
1
0
Change in Cash
30
10
-53
-80
282
132
-91
-148
-163

Global Institutional Holdings in Prothena Corporation plc

Funds
Holdings
Vanguard Group Inc
3.98%
ADAR1 Capital Management LLC
2.71%
Rock Springs Capital Management LP
0.92%
Morgan Stanley - Brokerage Accounts
2.32%
Mariner Wealth Advisors LLC
1.07%
See all

Insights on Prothena Corporation plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -125.76M → -21.58M (in $), with an average increase of 156.7% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, PRTA has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Prothena Corporation plc has experienced a drawdown of -86.3%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 79.4%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, PRTA stock has moved down by -86.3%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 4.42M → 21.0K (in $), with an average decrease of 72.3% per quarter

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
OrganisationProthena Corporation plc
Headquarters77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
IndustryBiotechnology
CEODr. Gene G. Kinney Ph.D.
E-voting on sharesClick here to vote

Key Management of Prothena Corporation plc

Name

Title

Mr. Tran B. Nguyen M.B.A.

Chief Financial Officer

Dr. Chad H. Swanson Ph.D.

Chief Development Officer

Mr. Mark C. Johnson C.F.A.

Vice President of Investor Relations

Phillip Dolan

Sr. Director & Head of Exploratory Research

Dr. Gene G. Kinney Ph.D.

President, CEO & Director

Mr. Brandon S. Smith

Chief Operating Officer

Dr. Wagner M. Zago Ph.D.

Chief Scientific Officer

Ms. Karin L. Walker CPA

Chief Accounting Officer & Controller

Mr. Michael J. Malecek

Chief Legal Officer & Company Secretary

Ms. Annie Evans Kingston

Chief Strategy Officer

FAQs

What is Prothena Corporation plc share price today?

Prothena Corporation plc share price today is $10.96 as on . Prothena Corporation plc share today touched a day high of $11.25 and a low of $10.89.

What is the 52 week high and 52 week low for Prothena Corporation plc share?

Prothena Corporation plc share touched a 52 week high of $11.69 on and a 52 week low of $4.32 on . Prothena Corporation plc stock price today i.e. is trending at $10.96,which is 6.24% down from its 52 week high and 153.70% up from its 52 week low.

What is Prothena Corporation plc's market capitalisation today?

Prothena Corporation plc market capitalisation is $0.00T as on .

How to invest in Prothena Corporation plc Stock (PRTA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Prothena Corporation plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Prothena Corporation plc Shares that will get you 0.1369 shares as per Prothena Corporation plc share price of $10.96 per share as on May 5, 2026 at 10:39 pm IST.

What is the minimum amount required to buy Prothena Corporation plc Stock (PRTA) from India?

Indian investors can start investing in Prothena Corporation plc (PRTA) shares with as little as ₹95.28 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.80 in Prothena Corporation plc stock (as per the Rupee-Dollar exchange rate as on ). Based on Prothena Corporation plc share’s latest price of $10.96 as on May 5, 2026 at 10:39 pm IST, you will get 0.9124 shares of Prothena Corporation plc. Learn more about fractional shares .

What are the returns that Prothena Corporation plc has given to Indian investors in the last 5 years?

Prothena Corporation plc stock has given -55.25% share price returns and 28.83% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?